Search Results - "Kazuki Sudo"

A novel combination of serum microRNAs for the detection of early gastric cancer by Abe, Seiichiro, Matsuzaki, Juntaro, Sudo, Kazuki, Oda, Ichiro, Katai, Hitoshi, Kato, Ken, Takizawa, Satoko, Sakamoto, Hiromi, Takeshita, Fumitaka, Niida, Shumpei, Saito, Yutaka, Ochiya, Takahiro

“…Background The aim of this study was to identify serum miRNAs that discriminate early gastric cancer (EGC) samples from non-cancer controls using a large…”
Get full text

Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice by Ida, Hanae, Koyama, Takafumi, Mizuno, Takaaki, Sunami, Kuniko, Kubo, Takashi, Sudo, Kazuki, Tao, Kayoko, Hirata, Makoto, Yonemori, Kan, Kato, Ken, Okusaka, Takuji, Ohe, Yuichiro, Matsui, Yoshiyuki, Yamazaki, Naoya, Ogawa, Chitose, Kawai, Akira, Narita, Yoshitaka, Esaki, Minoru, Yamamoto, Noboru

“…Previous clinical trials indicate that 10%–25% of patients received genomically matched therapy after comprehensive genomic profiling (CGP) tests. However, the…”
Get full text

First‐in‐human study of ONO‐4578, an antagonist of prostaglandin E2 receptor 4, alone and with nivolumab in solid tumors by Iwasa, Satoru, Koyama, Takafumi, Nishino, Makoto, Kondo, Shunsuke, Sudo, Kazuki, Yonemori, Kan, Yoshida, Tatsuya, Tamura, Kenji, Shimizu, Toshio, Fujiwara, Yutaka, Kitano, Shigehisa, Shimomura, Akihiko, Sato, Jun, Yokoyama, Fumiharu, Iida, Hiroyuki, Kondo, Maki, Yamamoto, Noboru

“…EP4, a prostaglandin E2 receptor, has shown an immunosuppressive activity on cancer cells. This first‐in‐human study evaluated ONO‐4578, a highly selective EP4…”
Get full text

Identification of novel SSX1 fusions in synovial sarcoma by Yoshida, Akihiko, Arai, Yasuhito, Satomi, Kaishi, Kubo, Takashi, Ryo, Eijitsu, Matsushita, Yuko, Hama, Natsuko, Sudo, Kazuki, Komiyama, Motokiyo, Yatabe, Yasushi, Shibata, Tatsuhiro, Ichikawa, Hitoshi, Ichimura, Koichi, Kawai, Akira, Mori, Taisuke

“…Synovial sarcoma is characterized by variable epithelial differentiation and specific SS18 - SSX gene fusions. The diagnosis is primarily based on phenotype,…”
Get full text

Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience by Uchihara, Masaki, Tanioka, Maki, Kojima, Yuki, Nishikawa, Tadaaki, Sudo, Kazuki, Shimoi, Tatsunori, Noguchi, Emi, Maeshima, Akiko Miyagi, Yonemori, Kan

“…Background Adrenocortical carcinoma (ACC) is a rare and aggressive disease that is often diagnosed at an advanced stage. There is no standard treatment for…”
Get full text

Identification of serum microRNAs predicting the response of esophageal squamous-cell carcinoma to nivolumab by Sudo, Kazuki, Kato, Ken, Matsuzaki, Juntaro, Takizawa, Satoko, Aoki, Yoshiaki, Shoji, Hirokazu, Iwasa, Satoru, Honma, Yoshitaka, Takashima, Atsuo, Sakamoto, Hiromi, Naka, Tomoaki, Sekine, Shigeki, Boku, Narikazu, Ochiya, Takahiro

“…Abstract Background Nivolumab, a programmed cell death protein 1 (PD-1) inhibitor, showed promising activity for the treatment of advanced esophageal…”
Get full text

Wavelet transform-based mode decomposition for EEG signals under general anesthesia by Yamochi, Shoko, Yamada, Tomomi, Obata, Yurie, Sudo, Kazuki, Kinoshita, Mao, Akiyama, Koichi, Sawa, Teiji

“…Background Mode decomposition methods are used to extract the characteristic intrinsic mode function (IMF) from various multidimensional time series signals…”
Get full text

Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma by Harada, Kazuto, Dong, Xiaochuan, Estrella, Jeannelyn S., Correa, Arlene M., Xu, Yan, Hofstetter, Wayne L., Sudo, Kazuki, Onodera, Hisashi, Suzuki, Koyu, Suzuki, Akihiro, Johnson, Randy L., Wang, Zhenning, Song, Shumei, Ajani, Jaffer A.

“…Background Programmed death ligand 1 (PD-L1) is a key protein upregulated by tumor cells to suppress immune responses. Tumor-associated macrophages (TAMs) play…”
Get full text

PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system by Shimoi, Tatsunori, Hamada, Akinobu, Yamagishi, Marifu, Hirai, Mitsuharu, Yoshida, Masayuki, Nishikawa, Tadaaki, Sudo, Kazuki, Shimomura, Akihiko, Noguchi, Emi, Yunokawa, Mayu, Yonemori, Kan, Shimizu, Chikako, Kinoshita, Takayuki, Fukuda, Takahiro, Fujiwara, Yasuhiro, Tamura, Kenji

“…PIK3CA mutations are common activating mutations associated with breast cancer (occurring in 20–30% of all cases) and are potent predictive markers for…”
Get full text

Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma by Kuroda, Takafumi, Ogiwara, Hideaki, Sasaki, Mariko, Takahashi, Kazuaki, Yoshida, Hiroshi, Kiyokawa, Takako, Sudo, Kazuki, Tamura, Kenji, Kato, Tomoyasu, Okamoto, Aikou, Kohno, Takashi

“…Ovarian clear cell carcinoma (OCCC) is often resistant to conventional, standard chemotherapy using cytotoxic drugs. OCCC harbors a unique genomic feature of…”
Get full text

Anesthetic Management of Thoracoscopic Pulmonary Cystectomy in a Patient With Fontan Circulation and Disturbed Lung Inflation During Leakage Testing: A Case Report by Higashi, Ayaka, Kinoshita, Mao, Sudo, Kazuki, Ueno, Hiroshi, Sawa, Teiji

“…Congenital heart disease may require multiple cardiac surgeries during childhood. Subsequent non-cardiac surgeries increase the perioperative bleeding and…”
Get full text

Lymphocyte-to-monocyte ratio as a prognostic and potential tumor microenvironment indicator in advanced soft tissue sarcoma treated with first-line doxorubicin therapy by Watanabe, Sho, Shimoi, Tatsunori, Nishikawa, Tadaaki, Kawachi, Asuka, Okuma, Hitomi Sumiyoshi, Tokura, Momoko, Yazaki, Shu, Mizoguchi, Chiharu, Arakaki, Motoko, Saito, Ayumi, Kita, Shosuke, Yamamoto, Kasumi, Kojima, Yuki, Sudo, Kazuki, Noguchi, Emi, Yoshida, Akihiko, Kawai, Akira, Fujiwara, Yasuhiro, Yonemori, Kan

“…Prognostic value of hematologic indices and their association with the tumor microenvironment (TME) remain unclear in advanced soft tissue sarcoma (STS). We…”
Get full text

High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: a retrospective study by Takamizawa, Shigemasa, Yazaki, Shu, Kojima, Yuki, Yoshida, Hiroshi, Kitadai, Rui, Nishikawa, Tadaaki, Shimoi, Tatsunori, Sudo, Kazuki, Okuma, Hitomi Sumiyoshi, Tanioka, Maki, Noguchi, Emi, Uno, Masaya, Ishikawa, Mitsuya, Kato, Tomoyasu, Fujiwara, Yasuhiro, Yonemori, Kan

“…Mesothelin (MSLN) is a cell-surface glycoprotein found in various solid tumours. Cancer therapies targeting MSLN have been developed in recent years; however,…”
Get full text

A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors by Yamamoto, Noboru, Shimizu, Toshio, Yonemori, Kan, Kitano, Shigehisa, Kondo, Shunsuke, Iwasa, Satoru, Koyama, Takafumi, Sudo, Kazuki, Sato, Jun, Tamura, Kenji, Tomomatsu, Junichi, Ono, Makiko, Fukuda, Naoki, Takahashi, Shunji

“…Summary Background This open-label, phase 1 study investigated TAS4464, a potent NEDD8-activating enzyme inhibitor, in patients with advanced/metastatic solid…”
Get full text

Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study by Takamizawa, Shigemasa, Shimoi, Tatsunori, Satomi-Tsushita, Natsuko, Yazaki, Shu, Okuya, Toshihiro, Kojima, Yuki, Sumiyoshi-Okuma, Hitomi, Nishikawa, Tadaaki, Tanioka, Maki, Sudo, Kazuki, Noguchi, Emi, Yonemori, Kan

“…Eribulin or capecitabine monotherapy is the next cytotoxic chemotherapy option for patients with metastatic or recurrent breast cancer who have previously…”
Get full text

Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study by Kitadai, Rui, Shimoi, Tatsunori, Sudo, Kazuki, Noguchi, Emi, Nagata, Yusuke, Sawada, Ryoichi, Takashima, Atsuo, Boku, Narikazu, Yonemori, Kan

“…Standard treatment for malignant peritoneal mesothelioma has not been established, and systemic chemotherapy is administered according to malignant pleural…”
Get full text

Clinical characteristics of primary cutaneous and subcutaneous Ewing sarcoma by Aiba, Hisaki, Kojima, Yuki, Shimoi, Tatsunori, Sudo, Kazuki, Yazaki, Shu, Imai, Toru, Yoshida, Akihiko, Iwata, Shintaro, Kobayashi, Eisuke, Kawai, Akira, Arakawa, Ayumu, Ogawa, Chitose, Kimura, Hiroaki, Yonemori, Kan

“…Abstract Objective Given the rarity of cutaneous/subcutaneous Ewing sarcoma, their clinical characteristics remain poorly understood. In this study, we aimed…”
Get full text

Diagnostic value of tumor markers in identifying favorable or unfavorable subsets in patients with cancer of unknown primary: a retrospective study by Takamizawa, Shigemasa, Shimoi, Tatsunori, Yoshida, Masayuki, Tokura, Momoko, Yazaki, Shu, Mizoguchi, Chiharu, Saito, Ayumi, Kita, Shosuke, Yamamoto, Kasumi, Kojima, Yuki, Sumiyoshi-Okuma, Hitomi, Nishikawa, Tadaaki, Noguchi, Emi, Sudo, Kazuki, Yonemori, Kan

“…Routine measurement of tumor markers is not recommended in daily clinical practice for patients with cancer of unknown primary (CUP). We evaluated the…”
Get full text

A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial by Chiba, Yohei, Sudo, Kazuki, Kojima, Yuki, Okuma, Hitomi, Kohsaka, Shinji, Machida, Ryunosuke, Ichimura, Masahiko, Anjo, Kenta, Kurishita, Kazumi, Okita, Natsuko, Nakamura, Kenichi, Kinoshita, Ichiro, Takahashi, Masanobu, Matsubara, Junichi, Kusaba, Hitoshi, Yonemori, Kan, Takahashi, Masamichi

“…Abstract Background Aberrant fibroblast growth factor receptor (FGFR) signaling can substantially influence oncogenicity. Despite that FGFR gene abnormality is…”
Get full text

Predictive value of peripheral blood markers in soft tissue sarcoma patients treated with eribulin by Ishihara, Shin, Ogura, Koichi, Maejima, Aiko, Shimoi, Tatsunori, Sudo, Kazuki, Kojima, Yuki, Fukushima, Suguru, Osaki, Shuhei, Kobayashi, Eisuke, Iwata, Shintaro, Matsui, Yoshiyuki, Yonemori, Kan, Kawai, Akira

“…eribulin, an anticancer agent that inhibits microtubule growth, along with trabectedin and pazopanib, has been approved for the treatment of advanced soft…”
Get full text